Paradigm Biopharmaceuticals ( (AU:PAR) ) has shared an announcement.
Paradigm Biopharmaceuticals has made significant progress in its global phase 3 clinical trial for iPPS, a treatment for knee osteoarthritis. The company secured ethics approval in Australia and appointed Advanced Clinical as the CRO to support the trial’s execution. With a cash balance of $24.56 million, Paradigm is poised to begin patient dosing in Q2 2025. The trial, involving 466 patients, will assess the efficacy of iPPS through various endpoints, including pain scores and imaging studies. Paradigm’s strategic initiatives, including a loyalty program to raise capital and active investor engagement, position the company well for future growth.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. is a company in the biotechnology industry, focusing on developing treatments for osteoarthritis. Its primary product is injectable Pentosan Polysulfate Sodium (iPPS), aimed at treating knee osteoarthritis. The company is actively engaged in clinical trials and regulatory processes to bring its products to market.
YTD Price Performance: -50.74%
Average Trading Volume: 10,782
Technical Sentiment Signal: Strong Buy
Current Market Cap: $74.57M
For an in-depth examination of PAR stock, go to TipRanks’ Stock Analysis page.